Effect of patient exclusion criteria on the efficacy of erythropoiesis-stimulating agents in patients with cancer-related anemia

Oncologist

Volumn 10, Issue 5, 2005, Pages 357-360

  Littlewood, Timothy J ^a   Schenkel, Brad ^b   Liss, Martin ^c,d  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^c Liberty Mutual Group   (United States)

^d POLICY ANALYSIS INC PAI   (United States)

Author keywords

Anemia; Cancer; Epoetin alfa; Erythropoiesis stimulating agents; Hemoglobin; Study design

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EPOETIN ALFA; ERYTHROPOIETIN, RECOMBINANT; HEMATINICS; HEMATOLOGIC NEOPLASMS; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN;

EID: 18444415188     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.10-5-357     Document Type: Article

References (9)

1. Rizzo JD, Lichtin AE, Woolf SH et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002;20:4083-4107.
2. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology - Cancer and Treatment-Related Anemia, Version 2.2004. Jenkintown, PA: National Comprehensive Cancer Network, 2004. Available at http://www.nccn. org/physician_gls/f_guidelines.html. Accessed February 11, 2005.
3. Dammacco F, Castoldi G, Rödjer S. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol 2001;113:172-179.
4. Österborg A, Brandberg Y, Molostova V et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 2002;20:2486-2494.
5. Littlewood TJ, Bajetta E, Nortier JW et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-2874.
6. Cazzola M, Beguin Y, Kloczko J et al. Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol 2003;122:386-393.
7. Littlewood TJ, Nortier J, Rapoport B et al. Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy. Hematol Oncol 2003;21:169-180.
8. Bokemeyer C, Littlewood T, Aapro M. Is once-weekly epoetin beta 'highly effective' in treating anaemia in patients with lymphoproliferative malignancy? Br J Haematol 2004;125:98-99.
9. Cazzola M, Messinger D, Battistel V et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphorna: dose finding and identification of predictors of response. Blood 1995;86:4446-4453.